Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab in First Line Treatment of Familiar Lymphohistiocytosis
NCT02472054Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2015
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in hemophagocytic lymphohistiocytosis (HLH), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Number of surviving patients until hematopoietic stem cell transplantation (HSCT) up to 4 months. Started Jun 2015; status: completed.
02
Drugs
alemtuzumab
03
Conditions
hemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT02472054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02472054.